title: [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefecture (2010-2011)].
abstract: We investigated genotype of penicillin-binding protein (PBP) genes and macrolide resistant genes, the serotypes and the susceptibility to antibacterial agents against 258 strains of Streptococcus pneumoniae isolated from medical facilities in Gifu and Aichi prefectures between January 2010 and March 2011. These results were compared with those against 377 strains of S. pneumoniae isolated in 2008-2009. The number of genotype penicillin-susceptible S. pneumoniae (gPSSP) with 3 normal PBP genes, genotype penicillin-intermediate S. pneumoniae (gPISP) with 1 or 2 normal PBP genes and genotype penicillin-resistant S. pneumoniae (gPRSP) with 3 abnormal genes was 11 (4.3%), 135 (52.3%) and 112 (43.4%) strains, respectively. The isolates with no macrolide-resistant gene, only mefA, only ermB, and both mefA and ermB were 17 (6.6%), 65 (25.2%), 143 (55.4%) and 33 (12.8%). The prevalent pneumococcal serotypes isolated from children were type 19F (18.2%), following by type 6A and 15 (11.7%). The potential coverage of pneumococcal conjugate vaccine (PCV7) was 43.8%. The prevalent pneumococcal serotypes isolated from adults were high in order of type 19F (12.8%), type 6A, 3 and 11 (10.3%), excepting non-typable strains (17.9%), and from elderly persons were type 6B (23.2%) and type 3 (13.4%). The MIC90 of each antibacterial agents was as follows; 0.0625 microg/mL for garenoxacin, 0.125 microg/mL for panipenem, 0.25 microg/mL for imipenem, doripenem, tosufloxacin, 0.5 microg/mL for cefditoren, meropenem, moxifloxacin, 1 microg/mL for amoxicillin, clavulanic acid/amoxicillin, cefteram, cefcapene, ceftriaxone, 2 microg/mL for benzylpenicillin, piperacillin, tazobactam/ piperacillin, pazufloxacin, levofloxacin, 4 microg/mL for cefdinir, flomoxef, 16 microg/mL for minocycline, > 64 microg/mL for clarithromycin, azithromycin and these MIC90s were about the same as those in 2008-2009.
authors: Research Laboratories, Toyama Chemical Co., Ltd.
authors: Maki
authors: M
authors: Eto
authors: Research Laboratories, Toyama Chemical Co., Ltd.
authors: Shingo
authors: S
authors: Mizunaga
authors: Research Laboratories, Toyama Chemical Co., Ltd.
authors: Yoshiko
authors: Y
authors: Fukuda
authors: Research Laboratories, Toyama Chemical Co., Ltd.
authors: Nobuhiko
authors: N
authors: Nomura
authors: Clinical Laboratories, Gifu Prefectural Tajimi Hospital.
authors: Yoko
authors: Y
authors: Matsukawa
authors: Development Division, Toyama Chemical Co., Ltd.
authors: Junichi
authors: J
authors: Mitsuyama
authors: Matsubara Otorhinolaryngology Clinic.
authors: Shigenori
authors: S
authors: Matsubara
authors: Gifu University of Medical Science.
authors: Kazukiyo
authors: K
authors: Yamaoka
authors: Division of Anaerobe Research, Life Science, Research Center, Gifu University.
authors: Kunitomo
authors: K
authors: Watanabe
authors: Department of Clinical Laboratory Medicine, Ogaki Municipal Hospital.
authors: Yuko
authors: Y
authors: Asano
authors: Department of Infection Control and Prevention, Aichi Medical University Hospital.
authors: Hiroyuki
authors: H
authors: Suematsu
authors: Department of Infection Control and Prevention, Aichi Medical University Hospital.
authors: Haruki
authors: H
authors: Sawamura
authors: Clinical Laboratories, Takayama Red Cross Hospital.
authors: Hikonori
authors: H
authors: Hashido
authors: Department of Clinical Infectious Diseases, Aichi Medical University.
authors: Yuka
authors: Y
authors: Yamagishi
authors: Department of Clinical Infectious Diseases, Aichi Medical University.
authors: Hiroshige
authors: H
authors: Mikamo
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005838:Genotype; D006801:Humans; D008826:Microbial Sensitivity Tests; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents